Dr Vishal Warke on Mind Map Training hosted Tathaastu Sales
Dr Vishal Warke, Biotechnology, at The SPECTACULAR First Mind Map Open Thane, hosted by Magadhi A Bam, Tathaastu Sales ! Next Mind Map Open Thane on 2nd and 16th Dec, 2012From:TathaastusalesViews:0 0ratingsTime:00:51More inEducation
Read the original here:
Dr Vishal Warke on Mind Map Training hosted Tathaastu Sales - Video
gene-X, Genetic engineering the Movie Official Trailer.mp4
This is the official traier of the short film "gene-X", made for the genetic engineering project by M.Sc. Biotechnology final year Students from VIT University, Vellore. (2011-13 Batch) Hope you will enjoy! Movie will go on air soon! Thank youFrom:Prasanna KarandikarViews:1 1ratingsTime:02:01More inPeople Blogs
Visit link:
gene-X, Genetic engineering the Movie Official Trailer.mp4 - Video
Biotechnology Laboratory System - Flinn Scientific
Watch as the Flinn Scientific Staff demonstrates the "Biotechnology Laboratory System." To view more Product Features videos by Flinn Scientific visit us at http://www.flinnsci.com ATTENTION: This demonstration is intended for and should only be performed by certified science instructors in a safe laboratory/classroom setting.From:FlinnScientificViews:0 0ratingsTime:01:25More inEducation
Here is the original post:
Biotechnology Laboratory System - Flinn Scientific - Video
Advances In Biosensors: Perspectives In Biosensors
ll4.me Advances In Biosensors: Perspectives In Biosensors There is a worldwide effort towards the development of bioanalytical devices that can be used for detection, quantification and monitoring of specific chemical species. In this context, biosensors represent an emerging trend in the diagnostics industry. A biosensor is a device that has a biological sensing element either intimately connected to or integrated within a transducer. The aim is to produce a digital electronic signal that is proportional to the concentration of a specific chemical or a set of chemicals. Biosensors are specific, rapid, cost-effective and easy to use devices that can be employed with minimal sample treatment. Biosensors have applications in many areas such as biotechnology, healthcare, pollution monitoring, food and agriculture product monitoring, the pharmaceuticals industry and defense. This reference text is devoted to the principles and applications of biosensors and meets the needs of academic institutes, research laboratories and the rapidly developing biosensor industry.Discusses novel ways that can be used to fabricate biosensors for a variety of applicationsBiosensors have applications in many scientific areasContributors are experts in their respective fields of research Publisher: JAI Press Illustration: N Language: ENG Title: Advances in Biosensors: Perspectives in Biosensors Pages: 00000 (Encrypted PDF) On Sale: 2003-07-09 SKU-13/ISBN: 9780444513373 Category: Science ...From:lesliecole347Views:0 0ratingsTime:00:10More inPeople Blogs
View post:
Advances In Biosensors: Perspectives In Biosensors - Video
Advances In Microbial Physiology
ll4.me Advances In Microbial Physiology Advances in Microbial Physiology Publisher: Academic Press Illustration: N Language: ENG Title: Advances in Microbial Physiology Pages: 00413 (Encrypted PDF) On Sale: 1992-06-24 SKU-13/ISBN: 9780120277339 Category: Science : Biotechnology Category: Science : Life Sciences - Microbiology Category: Science : Life Sciences - Biology Advances in Microbial Physiology Publisher: Academic Press Illustration: N Language: ENG Title: Advances in Microbial Physiology Pages: 00413 (Encrypted PDF) On Sale: 1992-06-24 SKU-13/ISBN: 97801202 science, biotechnology, life sciences, microbiologyFrom:louisesuper324Views:0 0ratingsTime:00:09More inPeople Blogs
Read the original post:
Advances In Microbial Physiology - Video
Development Of Sustainable Bioprocesses: Modeling And Assessment - , Arno PP Biwer
ll4.me Development Of Sustainable Bioprocesses: Modeling And Assessment - , Arno PP Biwer Bioprocess technology involves the combination of living matter (whole organism or enzymes ) with nutrients under laboratory conditions to make a desired product within the pharmaceutical, food, cosmetics, biotechnology, fine chemicals and bulk chemicals sectors.Industry is under increasing pressure to develop new processes that are both environmentally friendly and cost-effective, and this can be achieved by taking a fresh look at process development; - namely by combining modern process modeling techniques with sustainability assessment methods.Development of Sustainable Bioprocesses: Modeling and Assessmentdescribes methodologies and supporting case studies for the evolution and implementation of sustainable bioprocesses. Practical and industry-focused, the book begins with an introduction to the bioprocess industries and development procedures. Bioprocesses and bioproducts are then introduced, together with a description of the unit operations involved. Modeling procedures, a key feature of the book, are covered in chapter 3 prior to an overview of the key sustainability assessment methods in use (environmental, economic and societal). The second part of the book is devoted to case studies, which cover the development of bioprocesses in the pharmaceutical, food, fine chemicals, cosmetics and bulk chemicals industries. Some selected case studies include: citric acid, biopolymers ...From:kennethbishop324Views:0 0ratingsTime:00:12More inPeople Blogs
Go here to see the original:
Development Of Sustainable Bioprocesses: Modeling And Assessment - , Arno PP Biwer - Video
Til I forget my name
soundcloud.com ...Akkhail woke up and the future, utopia or dystopia...was there, vast horizons of blue skies on controlled expansions of integrated technology, seamless with nature. It was obvious that nanorobots were purifying the air, while the bioengineered plants were repairing two centuries of damages to the planet. The entire landscape was the result of robotics applied to nano and biotechnology. What was missing were humans. It was only after many hours of exploration that the first man appeared on a chair, in the patio of a beautiful villa integrated with the landscape: the sun and blue skies reflected n his virtual glasses, while a cable was connected to what obviously was the chip in his brain: he was immersed into a different world, a virtual one where he was just software, his consciousness merged with billion of other consciousness, in a network of souls that interacted at a level never reached by the stimuli of Akkhail #39;s time...From:Bugbe4rvirusViews:0 0ratingsTime:04:17More inMusic
More here:
Til I forget my name - Video
Portrait Of State-of-the-art Research At The Technical University Of Lisbon
ll4.me Portrait Of State-of-the-art Research At The Technical University Of Lisbon The Technical University of Lisbon (UTL) is celebrating its 75th anniversary this year. Being a jubilee occasion a full program of events took place, including a two day Symposium on the research at UTL. This Symposium addressed the state-of-art in major areas of excellence at UTL. This book, containing the edited version of the invited lectures, brings together in a review manner a comprehensive summary of high quality research contributions across basic and applied sciences. As a result a broad spectrum of topics is covered reflecting the areas at UTL where there is a worldwide recognition of expertise. The transdisciplinary nature of most areas aims to stress a sense of purpose in the work developed. The contributing papers are organized around the following major areas: Emergent areas (Nanosciences, Quantic Computations and Information, Smart Materials, Risk and Volatility in financial markets); Basic Sciences (Math, Physics, Chemistry, Materials); Social Sciences, Economics and Management Sciences; Life and Biotechnology Engineering; Public Health and Food Quality and Safety; Nature, Environment and Sustainability; Health and Sport sciences; Architecture, Urbanism, Arts and Design. EAN/ISBN : 9781402056901 Publisher(s): Springer Netherlands Format: ePub/PDF Author(s): Pereira, Manuel Seabra The Technical University of Lisbon (UTL) is celebrating its 75th anniversary this year. Being a ...From:louisesuper324Views:0 0ratingsTime:00:12More inPeople Blogs
The rest is here:
Portrait Of State-of-the-art Research At The Technical University Of Lisbon - Video
Molecular Biotechnology - Bernard R. Glick
ll4.me Molecular Biotechnology - Bernard R. Glick Acclaimed by students and instructors, Molecular Biotechnology is now in its fourth edition, bringing it thoroughly up to date with the latest findings and the latest industrial, agricultural, pharmaceutical, and biomedical applications. At the same time, the text maintains all the hallmarks that have made it a bestseller. These include its straightforward, jargon-free writing style and its extensive use of figures that help students make sense of complex biological systems and processes.Author: Glick, Bernard R. Publisher: ASM Press Illustration: N Language: ENG Title: Molecular Biotechnology Pages: 01018 (Encrypted PDF) On Sale: 2011-03-16 SKU-13/ISBN: 9781555814984 Category: Science : Life Sciences - Microbiology Acclaimed by students and instructors, Molecular Biotechnology is now in its fourth edition, bringing it thoroughly up to date with the latest findings and the latest industrial, agricultural, pharmac bernard r. glick, science, life sciences, microbiologyFrom:candacechamblee324Views:0 0ratingsTime:00:10More inPeople Blogs
Read the rest here:
Molecular Biotechnology - Bernard R. Glick - Video
ZURICH, Nov. 6, 2012 /PRNewswire/ --Cytos Biotechnology Ltd ("Cytos" or the "Company") announced today financial results and business highlights for the quarter ended September 30, 2012.
Highlights
Cytos completed its restructuring during the third quarter 2012 with the appointment of Dr.Christian Itin as Chief Executive Officer in October, taking office on November 5, 2012. Dr. Itin is also proposed to be elected to the Board of Directors and to chair the Board of Directors upon election at an Extraordinary Shareholders' Meeting to take place on November 20, 2012. Dr. Thomas Hecht and Mr. Jakob Schlapbach will step down from the Cytos Board at this meeting.
During the period, the Company also made good progress in preparing the Phase 2b clinical trial with its lead product candidate, CYT003, in allergic asthma which is expected to start in the fourth quarter. This important trial is aiming to recruit approximately 360 adult patients suffering from moderate to severe allergic asthma not sufficiently controlled on current standard therapy. The study is expected to be conducted at more than 90 centres in North America and Europe, and to read out top-line data in 2014.
Dr. Itin (age 48 yrs.) is the former President and Chief Executive Officer of Micromet Inc., a previously Nasdaq-listed biopharmaceutical company, with headquarters in the USA and a R&D center in Germany. Dr. Itin led Micromet as CEO from 2004 until its acquisition by Amgen for $1.2 billion in cash in March 2012. In total he spent 13 years in senior management roles at Micromet. Prior to joining Micromet in 1999, Dr. Itin co-founded Zyomyx, Inc., a protein chip company based in Hayward, CA, USA.
Dr. Itin was awarded a degree in biology and a Ph.D. in cell biology from the University of Basel. In addition, he has undertaken post-doctoral research at the Biocenter of Basel University and at the Stanford University School of Medicine.
The detailed Q3 Financial Report can be downloaded at http://www.cytos.com/userfiles/file/Cytos_Q3_2012_E.pdf
For further information please contact:
About Cytos Biotechnology Ltd Cytos Biotechnology Ltd is a Swiss public biotechnology company focused on the development of its lead product candidate CYT003 in allergic asthma. CYT003 has successfully completed a phase 2a trial in patients with persistent allergic asthma receiving standard inhaled corticosteroid (ICS) treatment, where it was shown to maintain lung function and asthma control as ICS treatment was withdrawn. CYT003 acts via a novel mechanism of action: it targets the Toll-like receptor 9 (TLR-9) pathway, which inhibits the immune response that leads to the allergic asthma response. Cytos plans to initiate Phase 2b studies with CYT003 in allergic asthma patients in 2012.
Cytos was founded in 1995 as a spinoff from the Swiss Federal Institute of Technology (ETH) in Zurich. It is located in Schlieren (Zurich). The Company is listed according to the Main Standard on the SIX Swiss Exchange Ltd under the symbol CYTN.
Read the original here:
Cytos Biotechnology Ltd Reports Third Quarter 2012 Financial Results, Recent Development and Outlook
Genetics-Iran-11-04-2012
DesiGirlsNetwork.Blogspot.com http Updates World News Plz Subscrib for Latest World News Iranian scientists have been working in the field of genetics for half of a century. Today the institute of genetic engineering and biotechnology is one of the leading research centers in the region. Its activities are aimed at enhancing the quality of life by better food medicine and environment. Amir Mehdi Kazemi reports on genetic engineering and biotechnology in Iran. Follow our Facebook on: http://www.facebook.com Follow our Twitter on: twitter.comFrom:UpdatesWorldNewsViews:0 0ratingsTime:06:41More inNews Politics
Go here to see the original:
Genetics-Iran-11-04-2012 - Video
SAN DIEGO, CA--(Marketwire - Nov 7, 2012) - COARE Biotechnology (COARE) and ChemDiv, Inc. (ChemDiv) announced today the formation of a strategic alliance that will offer a fully integrated gene-to-clinic services aimed at development of therapeutic agents that selectively affect cancer stem cells (CSC).
Under terms of this agreement, COARE contributes its pioneering research on the role of Doublecortin-like Kinase 1 (DCLK1) in proliferation and differentiation of CSC including relevant screening reagents and know-how. ChemDiv provides chemistry and biology expertise, including i) small molecule screening libraries, Medicinal Chemistry support, ii) assay adaptation, development and implementation, iii) in vivo testing and iv) advanced preclinical services including DMPK/tox. Dr. Ilya Okun, VP of Biology and CTO at ChemDiv, said: "COARE scientists, have identified a novel enzyme, DCLK1, which plays a key role in development of many solid tumors. This kinase is a promising and tractable target for the discovery of novel specific anti-cancer therapies. I am very excited that the collaboration between ChemDiv and COARE on this program will allow for discovery of new ways to treat a panel of cancers, for which there currently is no effective medicine."
Dr. Courtney W. Houchen, Chief Medical Adviser and cofounder, said, "We are excited at this partnership opportunity and the fact that this collaboration with ChemDiv will bring to the doorstep of both pharmaceutical and biotechnology companies worldwide, our research, expertise and our proprietary assays to help discover small molecules that target, and potentially eradicates or functionally inactivates the most resistant subpopulation of most tumors, the cancer stem cells."
About ChemDiv ChemDiv, Inc. is a Fully Integrated Target-to-Clinic Contract Research Organization (CRO) headquartered in San Diego, CA USA. The company features multiple research and development (R&D) subsidiaries in Russia, Ukraine and China as well as business and logistics operations around the world. We engage pharmaceutical and biotech partners by offering 'one stop' drug discovery and development services based on a project-, FTE- and risk sharing collaborative modes. More information about ChemDiv is available at http://www.chemdiv.com.
About COARE COARE Biotechnology is a research driven biotechnology company dedicated to developing novel anti-cancer therapeutic agents designed to treat solid tumor cancers headquartered in Oklahoma City, OK USA. Our agents are directed against DCLK1, a novel molecular target whose mechanism of action involves multi-pathway, multi-functional cancer inhibition. Recently completed research has shown that this stem cell related protein plays a functional role and is increased in human pancreatic cancer. This protein works to turn off natural tumor suppressors and turns on cancer-causing genes. We are determined to eradicate solid tumor cancers in our lifetime. For additional information about us go to http://www.coarebiotechnology.com
Read more from the original source:
Coare Biotechnology and ChemDiv Establish Co-Marketing and Service Collaboration
22. Pharmaceutical Biotechnology: Part IIa Pharmaceutical Biotechnology In the Genomics Era NQ
A genome is all the DNA in an organism, including its genes. Genes carry information for making all the proteins required by all organisms. What does it mean to the pharmaceutical enterprise to know all of the genes in humans, and other organisms? How does being able to rapidly and affordably sequence DNA affect our diagnostic capabilities and abilities to treat diseases, develop new vaccines and identify new emerging pathogens?From:Albert KauschViews:0 0ratingsTime:31:45More inScience Technology
LOS ANGELES--(BUSINESS WIRE)--
Puma Biotechnology, Inc. (PBYI), a development stage biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will present an overview of the Company at 2:00 p.m. EST on Wednesday, November 14, at the Lazard Capital Markets 9th Annual Healthcare Conference in New York City.
A live webcast will be available on the Companys website at http://www.pumabiotechnology.com. The presentation will be archived on the website and available for 30 days.
About Puma Biotechnology
Puma Biotechnology, Inc. is a development stage biopharmaceutical company that acquires and develops innovative products for the treatment of various forms of cancer. The Company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seeks to further develop those drug candidates for commercial use. The Company is initially focused on the development of PB272 (oral neratinib), a potent irreversible tyrosine kinase inhibitor, for the treatment of patients with HER2 positive metastatic breast cancer.
Further information about Puma Biotechnology may be found at http://www.pumabiotechnology.com.
Forward-Looking Statements:
This press release contains forward-looking statements that involve risks and uncertainties that could cause the Company's actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors, which include, but are not limited to, the risk factors disclosed in the periodic reports filed by the Company with the Securities and Exchange Commission from time to time. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company assumes no obligation to update these forward-looking statements, except as required by law.
View post:
Puma Biotechnology to Present at Lazard Healthcare Conference
19. Agricultural Biotechnology Part V. Renewable Energy and the Future of Humanity. NQ
What is the carrying capacity of the planet? How many people can we put here until there is a Tragedy of the Commons? Oil and fossils fuels took millions of years to make and are a finite resource that we are burning at an alarming rate and probably contributing to global climate change. What are the possible solutions for the future that are renewable and sustainable?From:Albert KauschViews:0 0ratingsTime:01:27:12More inScience Technology
Originally posted here:
19. Agricultural Biotechnology Part V. Renewable Energy and the Future of Humanity. NQ - Video
25. Medical Biotechnology: Part Ib. Stem Cells-Therapy and Medical Research NQ
Stem cell research has created national, if not global controversy. Why? What divides our thinking about stem cell research? This section provides the basics on stem cell research including: embryonic stem cells; adult stem cells; and, induced pluri-potent stem cells. Also discussed are their potential therapeutic application for degenerative diseases.From:Albert KauschViews:1 0ratingsTime:36:03More inScience Technology
Read the original:
25. Medical Biotechnology: Part Ib. Stem Cells-Therapy and Medical Research NQ - Video
24 . Medical Biotechnology: Part Ia. Some Background and Historical Highlights NQ
Before launching into the future of medical research, we take a look back, at history and how we got here with our current capabilities for treating medical conditions. But even before that, have you ever wondered how many bacteria we may contact when shaking someone #39;s hand? And how effective are those hand sanitizers? We look at a simple experiment designed to examine those questions using the students at the University of Rhode Island as a test case scenario. Then we look the development of some medical devices through history.From:Albert KauschViews:0 0ratingsTime:43:36More inScience Technology
See the original post here:
24 . Medical Biotechnology: Part Ia. Some Background and Historical Highlights NQ - Video
21. Pharmaceutical Biotechnology: Part Ib Emergent Technologies DNA-based Biotechnology NQ
With Recombinant DNA Drug development pharmaceutical biotechnology embraces the tools of genetic modification for new therapies. Similar to the technology introduced in the Agricultural Biotechnology section of this course, gene constructs can be made using DNA from different sources to make high value proteins that can be produced as injectable drugs. Insulin was one of the first recombinant DNA drugs to be made this way. Notice that recombinant insulin does not draw nearly the controversy as genetically modified tomatoes (even though they use the same technology). in this part we also examine the use of this technology for antibody based drugs and new vaccines.From:Albert KauschViews:0 0ratingsTime:58:56More inScience Technology
More here:
21. Pharmaceutical Biotechnology: Part Ib Emergent Technologies DNA-based Biotechnology NQ - Video
27 . Medical Biotechnology: Part II. Gene Therapy, Tissue Engineering and Nanotechnology
In theory, gene therapy offers a straight forward to the molecular treatment of various diseases, by using genes to prevent or treat disease by: Replacing a mutated gene(s) with a healthy copy; Inactivating/knocking out a mutated gene; or, Introducing new gene. Gene Therapy offers an approach to treating disease by either modifying the expressions of an individual #39;s genes or correction of abnormal genes. While this seems straight forward (ie replace or supply a healthy insulin gene in pancreatic cells of a diabetic) it has been difficult to actualize. Think here also about dual use problems (ie genetic doping for athletes, genetic modification enhancement for military personnel, and germline genetic engineering of humans with heritable genes). in this section we also review tissue engineering and some of the possibilities for nanotechnologies in medical devices. Nanosized GPS capable computers in our bloodstream?From:Albert KauschViews:0 0ratingsTime:36:53More inScience Technology
Read more from the original source:
27 . Medical Biotechnology: Part II. Gene Therapy, Tissue Engineering and Nanotechnology - Video
26. Medical Biotechnology: Part Ic. Animal and Human Cloning and Genetic Engineering NQ
Some of the same techniques described for stem cell research, have been extended and applied to animal cloning, creating part of the controversies surrounding both topics. What is cloning? Cloning an organism (as a totally different process distinguished from cloning a gene) is a process whereby all members are directly descended, asexually, from a single organism by......various ways, as we show in this section, and this demonstrates that all the information required for an organism and its development are in the a single cell. many animals have now been cloned, including, sheep (Dolly), cattle, pigs, mice, rats, fish, dogs, cats, horses, mules, and more recently monkeys. Can humans be cloned? Probably.From:Albert KauschViews:0 0ratingsTime:25:37More inScience Technology
See original here:
26. Medical Biotechnology: Part Ic. Animal and Human Cloning and Genetic Engineering NQ - Video